Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma
Teresa E. Williams(Novartis (Switzerland)), Daniel Poon(Rapt Therapeutics (United States)), Leonard Sung(Novartis (Switzerland)), Savithri Ramurthy(FuelCell Energy (United States)), Christopher M. McBride(Novartis (Switzerland)), Timothy Machajewski(Allogene Therapeutics (United States)), Darrin D. Stuart(Scorpion Therapeutics (United States)), Barry H. Levine(Novartis (Switzerland)), Joelle Verhagen(Novartis (Switzerland)), Kimberly Aardalen(Novartis (Switzerland)), William Antonios-McCrea(Novartis (Switzerland)), B.A. Appleton(Novartis (Switzerland)), Cynthia M. Shafer(Novartis (Switzerland)), Alicia K. Louie(Novartis (Switzerland)), Sharadha Subramanian(Novartis (Switzerland)), Abran Costales(Novartis (Switzerland)), Maureen McKenna(Novartis (Switzerland)), Payman Amiri(Novartis (Switzerland)), James Chou(Novartis (Switzerland)), Paul A. Renhowe(Novartis (Switzerland))
Cited by 54
Related Papers
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
|Nature|2013|735
Attitudes and perceptions of UK medical students towards artificial intelligence and radiology: a multicentre survey
|Insights into Imaging|2020|492
Food, Shelter and Safety Needs Motivating Homeless Persons' Visits to an Urban Emergency Department
|Annals of Emergency Medicine|2008|100